Van Elle Holdings Plc (AIM:VANL) delivered a resilient full-year performance amid challenging market conditions, highlighting steady progress across its core sectors—residential, infrastructure, and regional construction. Revenue on a continuing basis declined by 6%, largely due to project delays, subdued housing activity, and Building Safety Act disruptions. Despite this, the company maintained solid gross margins and a positive underlying profit before tax. A key highlight was a robust increase in the order book, underpinned by strategic wins in infrastructure and specialist piling, particularly in the high-growth energy sector. The acquisition of Albion Drilling and a sharpened focus on design-led, high-margin services position Van Elle for scalable growth in FY26 and beyond. The group’s capital-light innovations like Smartfoot and Screwfast continue to drive differentiation, while efforts to enhance return on capital—including transport fleet outsourcing and rig optimisation—are expected to boost EBITDA and operating margins towards targeted 6–7% levels. Although the Canada business is being discontinued, the balance sheet remains strong, supporting future investment and operational agility. Management remains confident in delivering market consensus for FY26, backed by momentum in industrial, energy, and early signs of housing recovery. Van Elle's strategic partnerships, diversified sector exposure, and embedded frameworks with Tier 1 contractors underpin a credible growth strategy focused on margin expansion and long-term shareholder value.

Shield Therapeutics Plc (AIM:STX) reported a strong Q2 2025 trading update, demonstrating accelerating momentum in ACCRUFeR® (oral iron therapy) growth, driven by enhanced digital marketing, optimised salesforce deployment, and increased market awareness. Net revenues for ACCRUFeR doubled to $12.8 million from Q1, supported by a 30% rise in prescriptions to 47,000 and a higher net selling price of $231. The company’s partnership with Viatris (80 sales reps combined) continues to underpin US commercial expansion, while digital campaigns and influencer outreach contributed to over 300 new prescribers monthly. Globally, Shield advanced partnerships across Europe, Canada, China, Korea, and Japan, securing milestone payments and regulatory progress, including paediatric label expansion. Consignment prescriptions declined to 23%, improving revenue quality. Shield reiterated its guidance to achieve cash flow positivity by year-end 2025, supported by strong IP through 2035, growing commercial traction, and a strategic mix of prescriber-focused and patient-driven engagement. The company also signaled plans to selectively expand its portfolio with commercial-stage assets leveraging its established infrastructure.

BlackRock Smaller Companies Trust Plc (LSE:BRSC) reaffirmed its long-term, bottom-up investment strategy focused on UK small and mid-cap growth companies. Portfolio manager Roland Arnold highlighted five core investment criteria—strong management, resilient balance sheets, consistent cash generation, long-term track records, and market-leading positions—as key drivers of stock selection. Despite recent underperformance linked to persistent outflows, a subdued IPO market, and lack of M&A exposure, the Trust sees significant upside potential. Current valuations for UK small and mid-cap growth stocks have compressed to levels not seen since the global financial crisis, creating compelling entry points for long-term investors. Historical data shows the segment’s consistent outperformance over decades, driven by compounding earnings growth. The Trust believes structural shifts in capital efficiency and scalability favour modern growth companies and that flows will return as macroeconomic and political clarity improves. With gearing currently at 6%, BlackRock remains cautiously positioned but ready to deploy capital as sentiment shifts. This investor update underscores confidence in the enduring relevance of its investment process and the long-term value opportunity within the UK’s undervalued small and mid-cap growth sector.

eEnergy Group Plc (AIM:EAAS) delivered a strong H1 2025 performance, marking a key inflexion point in its growth strategy and financial results. Revenue rose 67% year-on-year to £10.1 million, delivering the fifth consecutive year of growth, while adjusted EBITDA improved by £2.5 million and the business achieved positive cash flow of £0.8 million. Gross margin increased significantly to 41.6% (from 19.2%), driven by tighter financial controls, improved procurement, and a higher-quality sales mix. The company reported its strongest ever order book, with £83 million of pipeline generated year-to-date, including £38 million in investment-grade projects and £15 million in signed heads of terms for H2 delivery. Strategic progress includes rapid deployment of its £100 million Adaptive funding facility, expansion into higher education and healthcare sectors, and recurring revenue growth from its solar operations and maintenance business. EEnergy expects to deliver FY25 revenue of £28 million, with further growth targeted in FY26, supported by a lean cost base, scalable operations, and a unique off-balance sheet funding model. With a sharpened focus on cash generation, gross margin, and disciplined project selection, management remains confident in meeting full-year expectations and driving long-term shareholder value.

hVIVO Plc (AIM:HVO) delivered a robust investor update for H1 2025, reporting £24.2 million in revenue and an EBITDA margin of 12%, supported by strong operational efficiencies and cost controls. With a healthy cash position of £23.3 million and no debt, the company is actively executing its growth strategy through diversification and integration. Recent acquisitions of CRS and CryoStore have expanded service offerings, enabling cross-functional delivery across human challenge trials, clinical services, laboratory testing, and consultancy. The weighted order book stands at £40 million, underpinned by a strong sales pipeline and growing demand across therapeutic areas, notably cardiometabolic and obesity trials. hVivo confirmed full-year revenue guidance of £47 million and improved EBITDA expectations, reflecting enhanced performance and cancellation fee contributions. Integration of acquired entities is progressing well, unlocking cross-selling opportunities and operational synergies. While macroeconomic headwinds and industry volatility have impacted timelines, the company remains confident in securing significant new contracts before year-end. With market leadership in human challenge trials and expanding capabilities across the clinical research spectrum, hVivo is well-positioned to deliver long-term shareholder value and revenue growth heading into 2026.

ACG Metals Limited (LSE:ACG) delivered a strong H1 2025 investor update, highlighting robust operational performance, disciplined cost control, and a healthy capital structure. The company reported significant free cash flow generation, underpinned by its first-quartile cost position and high-grade production at the Gədəbəy asset, which is transitioning from gold to copper. Guidance for gold equivalent production was raised by 17%, reflecting improved recoveries and operational efficiencies. With EBITDA margins among the highest in the sector, ACG Metals continues to trade at a deep discount to peers on key valuation metrics such as EV/EBITDA and price-to-free cash flow. The sulphide expansion project remains on time and on budget, backed by strong liquidity, a simplified capital structure, and positive investor sentiment in both bond and equity markets. Management reaffirmed its growth strategy, focusing on acquiring producing or near-producing copper assets to capitalize on forecast market deficits from 2027. With M&A opportunities advancing and a clear path to scale, ACG Metals positions itself as an emerging pure-play copper growth story.

TheWorks.co.uk Plc (AIM:WRKS) reported a strong FY25 performance, underpinned by strategic progress, operational improvements, and clear financial momentum. EBITDA rose to £9.5 million, up from £6 million and ahead of market expectations, driven by 2.3% like-for-like store sales growth and significant product margin improvements. Revenue reached £277 million, with physical stores accounting for over 90% of sales. Despite a temporary decline in online sales, the company focused on profitability and improved margin performance. Its new “Elevating The Works” growth strategy—aimed at becoming the go-to destination for affordable, screen-free family activities—sets ambitious targets of £375 million in sales and a 6% EBITDA margin within five years. FY26 is off to a strong start, with 5% like-for-like sales growth in the first 11 weeks and upgraded guidance for £11 million EBITDA. The business continues to optimise its store estate, with 98% of locations now profitable, and plans to open 60 net new stores over the next five years. Strategic priorities include growing brand awareness, improving customer convenience, and operating efficiently—supported by cost savings, supplier negotiations, systems upgrades, and a new DC mezzanine expansion. With a compelling retail proposition, robust cash position, and rising market share across key categories like books, arts & crafts, and stationery, TheWorks.co.uk offers a credible and exciting investment case. Investors can expect continued growth in profitability, margin expansion, and shareholder value creation through disciplined capital allocation and reinvestment.

Me Group International Plc (LSE:MEGP) delivered a record first half performance for the six months ended 30 April 2025, reporting strong revenue, EBITDA growth, and cash generation despite FX headwinds. The group's strategy of diversifying its business mix, with a focus on expanding its high margin laundry operations, continues to drive robust financial results. Laundry now accounts for over a third of group vending revenue and nearly half of EBITDA, underpinned by a record 523 net new laundry installations in H1 and a target of 1,200 for the full year. Revenue grew 4.7%at constant currency, while EBITDA rose 6.4%, with margins expanding to 34.6%. Profit before tax increased 16.3%, supported by operational leverage and disciplined cost control. Me Group’s broad international footprint spans 48,500 machines across 16 countries, leveraging key retail partnerships and a proven, cash generative business model with rapid payback on capital investments. Interim dividends rose by over 11%, reflecting strong shareholder returns. Despite challenges in its legacy photo booth business, including a resolved supplier issue, and modest growth in Asia Pacific, the group remains confident in its growth strategy, driven by ongoing investment in R&D, innovation, and market expansion. Management reiterated its outlook for another year of record profitability in FY2025.

N4 Pharma PLC (AIM:N4P) delivered a comprehensive investor update outlining its strategy to unlock value through its proprietary Nuvec® delivery platform, designed to overcome critical challenges in RNA therapeutics, including targeted delivery and manufacturing scalability. With the RNA therapeutics market forecast to reach $18 billion by 2028, N4 Pharma is focused on monetizing Nuvec® through strategic partnerships and licensing agreements, while concurrently advancing its own RNA therapeutic pipeline, notably the N4 101 inflammatory bowel disease program, which recently delivered positive pre-clinical efficacy data. The company strengthened its leadership team and board, bolstering expertise in R&D, strategy, and business development to support its growth strategy. The investor presentation highlighted Nuvec®'s key differentiators — high drug loading capacity, targeted delivery potential, endosomal release efficiency, and manufacturing scalability — positioning it as a next-generation RNA delivery solution beyond current lipid nanoparticle and viral vector technologies. N4 Pharma emphasized its dual-track business model of platform partnering and proprietary asset development to drive revenue, reduce risk, and maximize shareholder value. Recent milestones include a £1.7 million fundraise and the launch of an expanded commercial data program, setting the stage for strategic licensing deals and value-inflection points in 2025 and beyond.